1. Practical Guidance on Using New Therapies for Relapsed/ Refractory Follicular Lymphoma and Chronic Lymphocytic Leukemia

3. Program Goals

4. Relapsed FL Case Study 1

5. Relapsed FL Factors to Consider

6. Case Study 1 Treatment Options

7. Idelalisib Updates From Phase 2 Trial

8. Idelalisib Supportive Care Considerations

9. Indolent NHL Emerging Treatment Options

10. Ibrutinib Phase 2 Trial in Relapsed/Refractory FL

11. Relapsed/Refractory FL Key Takeaways

12. Relapsed CLL Case Study 2

13. Case Study 2 Findings

14. Relapsed CLL Factors to Consider

15. Ibrutinib Phase 2 RESONATE-17 Trial

16. Idelalisib + Rituximab Pivotal Phase 3 Trial in Relapsed CLL

17. Relapsed/Refractory CLL Emerging Treatment Options

18. Relapsed/Refractory FL and CLL Summary and Future Directions

19. Abbreviations

20. Abbreviations (cont)

21. References

22. References (cont)

23. References (cont)

24. References (cont)

25. References (cont)

26. References (cont)